RT Book, Section A1 Rhee, June-Wha A1 Wu, Joseph C. A2 Fuster, Valentin A2 Narula, Jagat A2 Vaishnava, Prashant A2 Leon, Martin B. A2 Callans, David J. A2 Rumsfeld, John S. A2 Poppas, Athena SR Print(0) ID 1202441437 T1 Genomics And Epigenomics of Heart Diseases T2 Fuster and Hurst's The Heart, 15e YR 2022 FD 2022 PB McGraw-Hill Education PP New York, NY SN 9781264257560 LK accesscardiology.mhmedical.com/content.aspx?aid=1202441437 RD 2024/04/24 AB Chapter SummaryThis chapter discusses the genetics and epigenetics of cardiovascular disease (CVD) (see Fuster and Hurst’s Central Illustration). Following the advances in deoxyribonucleic acid (DNA) sequencing technologies, our knowledge of cardiovascular genetics and epigenetics has dramatically increased. While we previously understood the genetics of heart disease mainly in the context of syndromic diseases, caused by chromosomal abnormalities, and Mendelian diseases, caused by single-gene defects, we now appreciate the integral roles of noncoding genes, polygenic mechanisms, and epigenetics in mediating heart disease. Herein, we first review conventional genetic mechanisms of heart disease, including chromosomal anomaly-related congenital heart defects and monogenic diseases such as genetic cardiomyopathy, inherited cardiac arrhythmia, and familial hypercholesterolemia. We then discuss the evolving evidence of polygenic mechanisms in heart disease, presenting an example of coronary artery disease and how polygenic risk score is used in its risk stratification. Next, we review epigenetic regulation of gene expression and discuss its role in CVD pathogenesis. Finally, we conclude by discussing a number of emerging technologies, including genome editing technologies, human-induced pluripotent stem cells, and advanced sequencing and bioinformatics technologies, which can further advance our knowledge of genetics and epigenetics of heart disease.